Vu to, to discuss this.

So I can see the results here, uh, on the screen, and the majority of the people actually picked the right answer and, and that is, uh, counsel about, uh, the infection risk and malignancy risk and the need for, uh, monitoring, uh, AEs, um, as the, uh, next step.

And, and I can see here that, uh, in a certain region of the country, for example, in Florida where I am, um, malignancy, skin cancer is certainly a risk with certain agent.

Um, and, and so that should be part of your screening when the patient come in, uh, skin cancer in particular in, in my case.

So let's talk about the, the next, uh, item on the list here, new treatment pathways in gMG.

Um, and, uh, we'll discuss about the, uh, advances that we have in C5 inhibition.

Um, not so long ago, we, um, did not have any of these new agents and, and that changed in 2017 when we pretty much opened up the current era of treatment of, uh, gMG.

Yeah.

So let me talk to you about...

GMG and the high costs of diagnostic delay.

So this patient has been going on with her symptoms for about 14 months.

Some people would do antibody testing sequentially.

I usually do all three about the same time because doing sequentially will cost you a few weeks at minimum and maybe more.

And we know that delay can lead to several disadvantages.

Anyway, MG is sort of a rare disease.

Rosanilizumab

So let me talk to you about...

GMG and the high costs of diagnostic delay.

So this patient has been going on with her symptoms for about 14 months.

Some people would do antibody testing sequentially.

I usually do all three about the same time because doing sequentially will cost you a few weeks at minimum and maybe more.

And we know that delay can lead to several disadvantages.

Anyway, MG is sort of a rare disease.

Rosanilizumab

Downloadable slides and practice aids are also available.

Hello, I am Do-Dr. Tuan Vu.

I'm a professor of neurology at the University of South Florida in Tampa.

Uh, thank you so much for joining this unique educational activity titled "Generalized Myasthenia Gravis Across Serological Subtypes: Challenges in Diagnosis and Treatment, uh, Personalization." Today, we will learn that the pathophysiology and serologic heterogeneity of, uh, generalized myasthenia gravis can directly shape disease course, symptom burden, and treatment response.

Accurate antibody subtype identification is essential to diagnosis and drives meaningful differences in clinical management.

Targeted therapies for gMG can and should be selected and sequenced based on individual patient subtype, antibody status, disease severity, and lifestyle factors.

To illustrate, um, our, uh, understanding today, we'll, um, talk about this patient, Vicky.

Downloadable slides and practice aids are also available.

Hello, I am D-Dr. Tuan Vu.

I'm a professor of neurology at the University of South Florida in Tampa.

Uh, thank you so much for joining this unique educational activity titled "Generalized Myasthenia Gravis Across Serological Subtypes, Challenges in Diagnosis and Treatment, uh, Personalization." Today, we will learn that the pathophysiology and serologic heterogeneity of, uh, generalized myasthenia gravis can directly shape disease course, symptom burden, and treatment response.

Accurate antibody subtype identification is essential to diagnosis and drives meaningful differences in clinical management.

Targeted therapies for gMG can and should be selected and sequenced based on individual patient subtype, antibody status, disease severity, and lifestyle factors.

To illustrate, um, our, uh, understanding today, we'll, um, talk about this patient, Vicky.

Downloadable slides and practice aids are also available.

Hello, I am D-Dr. Tuan Vu.

I'm a professor of neurology at the University of South Florida in Tampa.

Uh, thank you so much for joining this unique educational activity titled "Generalized Myasthenia Gravis Across Serological Subtypes: Challenges in Diagnosis and Treatment, uh, Personalization." Today, we will learn that the pathophysiology and serologic heterogeneity of, uh, generalized myasthenia gravis can directly shape disease course, symptom burden, and treatment response.

Accurate antibody subtype identification is essential to diagnosis and drives meaningful differences in clinical management.

Targeted therapies for gMG can and should be selected and sequenced based on individual patient subtype, antibody status, disease severity, and lifestyle factors.

To illustrate, um, our, uh, understanding today, we'll, um, talk about this patient, Vicky.